These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32592669)

  • 1. Cabotegravir, a new option for PrEP.
    Kirby T
    Lancet Infect Dis; 2020 Jul; 20(7):781. PubMed ID: 32592669
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
    Levy ME; Agopian A; Magnus M; Rawls A; Opoku J; Kharfen M; Greenberg AE; Kuo I
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):e80-e82. PubMed ID: 33148996
    [No Abstract]   [Full Text] [Related]  

  • 3. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).
    Rael CT; Lopez-Ríos J; McKenna SA; Das D; Dolezal C; Abascal E; Carballo-Diéguez A; Schnall R; Hope TJ; Bauermeister J; Bockting W
    AIDS Behav; 2021 Dec; 25(12):4180-4192. PubMed ID: 34216284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV Pre-exposure Prophylaxis Indication and Readiness Among HIV-Uninfected Transgender Women in Ho Chi Minh City, Vietnam.
    Oldenburg CE; Le B; Toan T; Thien DD; Huyen HT; Friedman MR; Stall R; Colby D
    AIDS Behav; 2016 Dec; 20(Suppl 3):365-370. PubMed ID: 27435073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.
    Kerrigan D; Mantsios A; Grant R; Markowitz M; Defechereux P; La Mar M; Beckham SW; Hammond P; Margolis D; Murray M
    AIDS Behav; 2018 Nov; 22(11):3540-3549. PubMed ID: 29290075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
    Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
    J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis.
    Ahluwalia AK; Inzaule S; Baggaley RC; Vitoria M; Schaefer R; Schmidt HA; Rodolph M; Giron A; Jordan MR
    AIDS; 2022 Nov; 36(13):1897-1898. PubMed ID: 36172874
    [No Abstract]   [Full Text] [Related]  

  • 9. Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.
    Rael CT; Martinez M; Giguere R; Bockting W; MacCrate C; Mellman W; Valente P; Greene GJ; Sherman S; Footer KHA; D'Aquila RT; Carballo-Diéguez A
    AIDS Behav; 2018 Nov; 22(11):3627-3636. PubMed ID: 29589137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women.
    Sevelius JM; Keatley J; Calma N; Arnold E
    Glob Public Health; 2016; 11(7-8):1060-75. PubMed ID: 26963756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study.
    Smith JA; Garnett GP; Hallett TB
    J Infect Dis; 2021 Oct; 224(7):1179-1186. PubMed ID: 32492704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals.
    Klein A; Golub SA
    AIDS Patient Care STDS; 2019 Jun; 33(6):262-269. PubMed ID: 31166785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of trans women in pre-exposure prophylaxis trials: a review.
    Escudero DJ; Kerr T; Operario D; Socías ME; Sued O; Marshall BD
    AIDS Care; 2015; 27(5):637-41. PubMed ID: 25430940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Setting the scene, setting the targets. The Joint United Nations Programme on HIV/AIDS prevention targets of 2016 and estimating global pre-exposure prophylaxis targets.
    Coleman R
    Sex Health; 2018 Nov; 15(6):485-488. PubMed ID: 30496717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [News in HIV infection, long-acting injectable treatments].
    Nawej Tshikung O; Segeral O; Cavassini M; Calmy A
    Rev Med Suisse; 2023 Feb; 19(812):243-249. PubMed ID: 36723657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-related care for transgender people: A systematic review of studies from around the world.
    Vaitses Fontanari AM; Zanella GI; Feijó M; Churchill S; Rodrigues Lobato MI; Costa AB
    Soc Sci Med; 2019 Jun; 230():280-294. PubMed ID: 31035207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.
    Lions C; Cabras O; Cotte L; Huleux T; Gagneux-Brugnon A; Makinson A; Cabié A; Bonnet B; Duvivier C; Hocqueloux L; Cua E; Cheret A; Hustache-Mathieu L; Obry-Roguet V; Jacomet C; Poizot-Martin I;
    BMC Infect Dis; 2019 Mar; 19(1):278. PubMed ID: 30909885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities.
    Restar AJ; Kuhns L; Reisner SL; Ogunbajo A; Garofalo R; Mimiaga MJ
    AIDS Behav; 2018 Nov; 22(11):3649-3657. PubMed ID: 29713838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges.
    Veloso VG; Mesquita F; Grinsztejn B
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20010. PubMed ID: 26198347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.